Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Uniqure NV
UQ1Current price
6.29 EUR
-0.72 EUR (-10.25%)
Last closed
6.8 USD
Company
www.uniqure.com
ISIN
NL0010696654
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
379 708 736 USD
Yield for 12 month
+1.43 %
1Y
3Y
5Y
10Y
15Y
UQ1
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Address: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19 USDP/E ratio
–Dividend Yield
–Current Year
+15 843 000 USD
Last Year
+106 483 000 USD
Current Quarter
+2 287 000 USD
Last Quarter
+11 126 000 USD
Current Year
+2 215 000 USD
Last Year
+103 140 000 USD
Current Quarter
+2 023 000 USD
Last Quarter
+995 000 USD
Key Figures UQ1
1 year
3 years
5 years
10 years
EBITDA
-217 116 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-17.12 %
PEG Ratio
–
Return On Equity TTM
-126.41 %
Wall Street Target Price
19 USD
Revenue TTM
27 707 000 USD
Book Value
4.34 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
359.4 %
Dividend Yield
–
Gross Profit TTM
-87 370 000 USD
Earnings per share
-4.95 USD
Diluted Eps TTM
-4.95 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-18.2 %
Profit Margin
–
Dividend Analytics UQ1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History UQ1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
31.01.2014
Dividend Date
–
Stock Valuation UQ1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
27.933
Enterprise Value Revenue
0.422
Price Sales TTM
13.7044
Enterprise Value EBITDA
0.9891
Price Book MRQ
6.8023
Financials UQ1
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators UQ1
For 52 weeks
3.73 USD
11.35 USD
50 Day MA
5.77 USD
Shares Short Prior Month
5 257 182
200 Day MA
5.72 USD
Short Ratio
7.31
Shares Short
5 733 489
Short Percent
11.9 %
BeatStart